General MedicationsORALStandard
STEGLUJAN
ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE
Standard Dose
5MG;EQ 100MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview STEGLUJAN is listed in Drugs@FDA under application 209805 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE Form and strength TABLET;ORAL - 5MG;EQ 100MG BASE Sponsor MSD SUB MERCK Submission history Latest submission status date: 2024-12-20 00:00:00.
Structured Monograph
Clinical summary
Approval overview STEGLUJAN is listed in Drugs@FDA under application 209805 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE Form and strength TABLET;ORAL - 5MG;EQ 100MG BASE Sponsor MSD SUB MERCK Submission history Latest submission status date: 2024-12-20 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.